financetom
Business
financetom
/
Business
/
CyberArk Software Q4 Non-GAAP Net Income Declines, Revenue Rises; Q1, 2025 Outlook Issued
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CyberArk Software Q4 Non-GAAP Net Income Declines, Revenue Rises; Q1, 2025 Outlook Issued
Feb 13, 2025 5:00 AM

07:39 AM EST, 02/13/2025 (MT Newswires) -- CyberArk Software ( CYBR ) reported Q4 non-GAAP net income Thursday of $0.80 per diluted share, down from $0.81 a year earlier.

Analysts polled by FactSet expected $0.72.

Revenue for the quarter ended Dec. 31 was $314.4 million, compared with $223.1 million a year earlier.

Analysts surveyed by FactSet expected $301.3 million.

For Q1, the company expects non-GAAP net income per diluted share of $0.74 to $0.81 on total revenue of $301 million and $307 million. Analysts surveyed by FactSet expect earnings of $0.77 on revenue of $300.9 million.

The company said it expects 2025 non-GAAP diluted net income of $3.55 to $3.70. Analysts surveyed by FactSet expect $3.62. Revenue for the year is expected to be $1.31 billion to $1.32 billion. Analysts polled by FactSet expect $1.30 billion.

Shares of CyberArk were up 4% in recent premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
China's Innovent says its GLP-1 works better than Novo's semaglutide in diabetes study
Oct 26, 2025
SHANGHAI, Oct 27 (Reuters) - China's Innovent Biologics ( IVBXF ) said on Monday its GLP-1 injection led to more weight loss and better control of blood sugar in patients with diabetes than injectable semaglutide, the active ingredient in Novo Nordisk's diabetes and weight-loss medicines. The late-stage head-to-head trial compared different doses of the two drugs in patients with diabetes...
Toyota September output grows for fourth stright month, aided by strong US demand
Toyota September output grows for fourth stright month, aided by strong US demand
Oct 26, 2025
TOKYO (Reuters) -Toyota Motor ( TM ) on Monday said its worldwide production increased by more than 10% in September and rose for a fourth straight month, as both sales and output increased in the U.S., the Japanese automaker's top market. Toyota's ( TM ) global output for September grew 11% from a year earlier to 918,146 vehicles. Production for...
HSBC to take $1.1 billion hit after Luxembourg court ruling in Madoff case
HSBC to take $1.1 billion hit after Luxembourg court ruling in Madoff case
Oct 26, 2025
(Reuters) - HSBC Holdings ( HSBC ) said on Monday it will book a $1.1 billion provision in its third-quarter results after losing part of an appeal in a long-running lawsuit tied to Bernard Madoff's Ponzi scheme. HSBC ( HSBC ) acted as a service provider to several funds that invested with Bernard L. Madoff Investment Securities LLC. Herald Fund...
Luxury brands turn on the charm in China to kindle nascent spending recovery
Luxury brands turn on the charm in China to kindle nascent spending recovery
Oct 26, 2025
SHANGHAI (Reuters) -As Chinese shoppers dip toes back in the luxury pool, brands are targeting economically resilient high-earners with distinctive, personalised experiences as their focus shifts more to market share than growth. Firms like LVMH and Hermes increasingly offer intimate dinners and large-scale shows, as well as stores with private shopping areas and exclusive elevator access for the VIPs they...
Copyright 2023-2026 - www.financetom.com All Rights Reserved